MET Inhibition in Advanced NSCLC: Molecular Testing for METex14 and Emerging Options

MET Inhibition in Advanced NSCLC: Molecular Testing for METex14 and Emerging Options (May 2020)

Saturday, May 30, 2020
Webinar -- 7:00 PM CT
https://www.clinicaloptions.com/NSCLCChicago2020Join

Agenda

METex14: Mastering the Features of a New Target in NSCLC – Luis Paz-Ares, MD, PhD

  • Role of METex14 alterations in tumorigenesis
  • Incidence of METex14 alterations
  • METex14 mutations vs MET amplification
  • Panel case discussion: Who should be tested?

Testing for METex14 in NSCLC – Luis Paz-Ares, MD, PhD

  • Testing for METex14 with next-generation sequencing (NGS)
  • METex14 as a target for selective inhibitors
  • Panel case discussion: Application of NGS testing in today’s clinic

METex14 Inhibitors on the Horizon – D. Ross Camidge, MD, PhD, and Karen Reckamp, MD, MS

  • Tepotinib (phase II VISION trail)
  • Capmatinib (phase II GEOMETRY trial)
  • Savolitinib
  • Crizotinib, cabozantinib, and other less selective MET inhibitors
  • Ongoing research
  • Panel case discussion: Putting emerging data into practice

Final Panel Discussion and Audience Question and Answer Session

Faculty

Program Director
Luis Paz-Ares, MD, PhD

Faculty
D. Ross Camidge, MD, PhD

Faculty
Karen Reckamp, MD, MS

Professor of Medicine
Director
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with MET-altered NSCLC.

Target Audience
This program is intended for global medical oncologists, pulmonologists and other healthcare providers who care for patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the rationale for METex14 as a targetable alteration in NSCLC
  • Evaluate the available testing platforms and use of tissue and plasma biopsies to assess METex14 in patients with NSCLC
  • Discuss the available clinical evidence for selective MET inhibitors in METex14-altered NSCLC, including an assessment of relative efficacy and central nervous system responses
  • Appropriately manage treatment-related adverse events associated with MET targeted agents used in patients with advanced-stage NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.